Tag Archives: Polyclonal antibody treatment for COVID-19 moves to phase 3 trial at UT Southwestern

Researchers at the University of Texas Southwestern Medical Center are studying a polyclonal antibody therapy to treat nonhospitalized people with early COVID-19 as part of a national effort to keep patients with the virus out of the hospital. The polyclonal antibody treatment, called SAB-185, is the first of its kind in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, …

Read More »